Solid Biosciences Doses First Participant in First-in-Class Clinical Trial Evaluating Gene Therapy for the Treatment of Friedreich’s Ataxia 

Solid Biosciences’ investigational gene therapy for Friedreich’s Ataxia, a rare, inherited, progressive neuromuscular disease (SGT-212), was developed in part by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine. Initial trial data is expected in the second half of 2026. Read more here.